DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Ablation of Renal Masses Outcomes Registry (ARMOR): Ablation Procedure and Quality of Life Assessment

Information source: Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Renal Cancer

Intervention: (EORTC QLQ-C30) questionnaire (Behavioral); EuroQol EQ-5D 7-item questionnaire (Behavioral)

Phase: N/A

Status: Recruiting

Sponsored by: Memorial Sloan Kettering Cancer Center

Official(s) and/or principal investigator(s):
Jeremy Durack, MD, Principal Investigator, Affiliation: Memorial Sloan Kettering Cancer Center

Overall contact:
Jeremy Durack, MD, Phone: 212-639-4898

Summary

The purpose of this study is to better understand how effective ablation is for destroying tumor cells in the kidney and whether quality of life is improved for patients. Participation in ARMOR may involve retrospective data collection only, combined retrospective and prospective data collection, or prospective data collection

Clinical Details

Official title: Ablation of Renal Masses Outcomes Registry (ARMOR): Ablation Procedure and Quality of Life Assessment

Study design: Observational Model: Cohort

Primary outcome: assess renal ablation outcomes

Secondary outcome:

differences in imaging characteristics

Assess the progression of imaging findings

Radiation exposure

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria: Retrospective enrollment:

- Patients having undergone percutaneous, open or laparoscopic energy ablation of a renal

mass. Prospective enrollment:

- Patients scheduled to undergo, rather than having undergone, percutaneous, open or

laparoscopic energy ablation of a renal mass. Exclusion Criteria:

- Patients not having undergone, or considered candidates for percutaneous, open or

laparoscopic energy ablation of a renal mass

- Non-English speaking patients

- Patients under the age of 18.

Locations and Contacts

Jeremy Durack, MD, Phone: 212-639-4898

University of Maryland Medical Center, Baltimore, Maryland 21201, United States; Recruiting
Richard Howard, MD
Richard Howard, MD, Principal Investigator

Memorial Sloan-Kettering Cancer Center, New York, New York 10065, United States; Recruiting
Jeremy Durack, MD, Phone: 212-639-4898
Stephen Solomon, MD, Phone: 212-639-5012
Jeremy Durack, MD, Principal Investigator

Thomas Jefferson University Hospital, Philadelphia,, Pennsylvania 19107, United States; Recruiting
Colette Shaw, MD
Colette Shaw, MD, Principal Investigator

Rhode Island Hospital, Providence, Rhode Island 02903, United States; Recruiting
Damian Dupuy, MD
Damian Dupuy, MD, Principal Investigator

Additional Information

Memorial Sloan-Kettering Cancer Center

Starting date: June 2013
Last updated: May 20, 2015

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017